Aethlon Medical (NASDAQ:AEMD) Now Covered by StockNews.com

Analysts at StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report issued on Sunday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright cut their price target on shares of Aethlon Medical from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, June 24th.

Aethlon Medical Trading Down 1.6 %

Shares of NASDAQ AEMD opened at $0.47 on Friday. The stock has a market capitalization of $6.48 million, a PE ratio of -0.10 and a beta of 1.72. Aethlon Medical has a 12-month low of $0.24 and a 12-month high of $2.40. The stock’s fifty day simple moving average is $0.39 and its two-hundred day simple moving average is $0.77.

Aethlon Medical (NASDAQ:AEMD) last announced its earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.10. During the same quarter in the prior year, the company earned ($1.30) earnings per share. On average, equities analysts predict that Aethlon Medical will post -1.1 earnings per share for the current fiscal year.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.